Corvette coupe raises $125,000 for cancer investigations at TGen

January 25, 2012

SCOTTSDALE, Ariz. -- Auction of a 1993 Chevrolet Corvette 40th Anniversary coupe raised $125,000 at the 41st Barrett-Jackson Scottsdale Auction, benefiting cancer research at the Translational Genomics Research Institute (TGen).

Proceeds go to the Barrett-Jackson Cancer Research Fund at TGen, in Memory of Russ and Brian Jackson. The fund is a salute to auction Chairman and CEO Craig Jackson's father, Russ, and brother, Brian, whose lives were cut short by colon cancer.

The ruby red 1993 Corvette is one of the 40th anniversary models of this legendary sports car. The first Corvette was built in 1953.

The car previously raised more than $200,000 for non-profit TGen research. The Corvette was sold and donated back several times during the 2011 auction, overseen by an emotional Craig Jackson.

This year, the Corvette was auctioned during Barrett-Jackson's evening prime time in Scottsdale on Saturday, Jan. 21, when many of the most expensive collector cars were featured.

The car raised $120,000 through auction, during which one member of the Barrett-Jackson audience also volunteered a separate $5,000 donation to TGen.

"Auction proceeds from this car are just a part of our ongoing commitment to raising funds and awareness about the tremendous work being done by TGen. I am so energized and honored by the research being done in memory of my dad and brother," Craig Jackson said.

Besides its annual Scottsdale event, Barrett-Jackson also conducts collector car auctions each year in: Palm Beach, Fla.; Orange County, Calif.; and Las Vegas, Nev.

Money raised by Barrett-Jackson supports TGen's research into colon and prostate cancer at TGen's Russ and Brian Jackson Research Laboratory, which is supported by the Barrett-Jackson Cancer Research Fund at TGen. This effort has become a fundraising focus at each of the four Barrett-Jackson collector car auctions. Craig Jackson has acted as a national spokesperson, spreading the word about how the fund supports research into both colon and prostate cancer, and how the research may lead to improved quality of life for cancer patients.

"The Barrett-Jackson team is helping to bring TGen's personalized approach to patients who are battling cancer right now," said Michael Bassoff, President of the non-profit TGen Foundation. "This research focuses on providing patients with the right treatment in the right dosage at the right time.''

Nearly 140,000 Americans are diagnosed annually with colon cancer, which each year kills nearly 50,000 patients, the third-leading cause of cancer death in the U.S.

An additional 240,000 American men are annually diagnosed with prostate cancer, which each year kills nearly 34,000 patients, the second-leading cause of cancer death among men in the U.S.

The Barrett-Jackson Scottsdale auction helped raise $5.8 million for local and national charities.
About The Barrett-Jackson Auction Company

Established in 1971 and headquartered in Scottsdale, Ariz., Barrett-Jackson specializes in providing products and services to classic and collector car owners, astute collectors and automotive enthusiasts around the world. The company produces the "World's Greatest Collector Car Events™" in Scottsdale, Palm Beach, Fla., Las Vegas and Orange County, Calif. For more information about Barrett-Jackson, visit or call 480-421-6694.

About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit:

Press Contact:

Steve Yozwiak
TGen Senior Science Writer

The Translational Genomics Research Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to